DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
51 hedge funds and large institutions have $12.7M invested in DMK Pharmaceuticals Corporation Common Stock in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
5% more capital invested
Capital invested by funds: $12.1M → $12.7M (+$592K)
3% more call options, than puts
Call options by funds: $718K | Put options by funds: $696K
2% less funds holding
Funds holding: 52 → 51 (-1)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$2.68M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$435K |
| 3 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
+$243K |
| 4 |
VF
Virtu Financial
New York
|
+$91.6K |
| 5 |
BlackRock
New York
|
+$79.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$983K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$191K |
| 3 |
Millennium Management
New York
|
-$151K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$129K |
| 5 |
Goldman Sachs
New York
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Goldman Sachs
New York
| – | -$124K | -505 | Closed |
|
|
52
Simplex Trading
Chicago,
Illinois
| – | -$129K | -481 | Closed |
|
|
BCM
53
BlueCrest Capital Management
St Helier,
Jersey
| – | -$72K | -294 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$6K | -24 | Closed |
|
55
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$4K | -14 | Closed |
|
|
CG
56
Cutler Group
San Francisco,
California
| – | -$2.14K | -8 | -67% |
|
|
WAS
57
Winch Advisory Services
Appleton,
Wisconsin
| – | -$1.34K | -5 | -83% |
|
|
SWP
58
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$1K | -4 | Closed |
|
DMK Hedge Fund Activity: Q2 2018 in Review
51 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2018, worth a combined $12.7M — up 4.9% from $12.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DMK positions and 7 closed out — a net gain of 1 holder — while 9 added to existing stakes and 14 trimmed.
The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $2.68M. The largest seller was Morgan Stanley, cutting an estimated $983K.
- 51 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2018, down from 52 in Q1 2018.
- Funds reported $12.7M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2018, up 4.9% quarter-over-quarter.
- 8 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2018 and 7 closed out, a net change of +1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2018 was DekaBank Deutsche Girozentrale, an estimated $2.68M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2018 was Morgan Stanley, an estimated $983K sold.
Based on aggregated 13F filings for Q2 2018.